Screener
Enliven Therapeutics ELVN Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $132,184 | $98,896 |
| Marketable securities | 320,217 | 363,725 |
| Prepaid expenses and other current assets | 10,736 | 12,257 |
| Total current assets | 463,137 | 474,878 |
| Property and equipment, net | 20 | 34 |
| Operating lease right-of-use assets | 290 | 383 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's short-term investments?
- Enliven Therapeutics (ELVN) reported short-term investments of $320.22M in Q1 2026.
- How has Enliven Therapeutics's short-term investments changed year-over-year?
- Enliven Therapeutics's short-term investments increased by 70.5% year-over-year, from $187.85M to $320.22M.
- What is the long-term trend for Enliven Therapeutics's short-term investments?
- Over 5 years (2020 to 2025), Enliven Therapeutics's short-term investments has grown at a 55.1% compound annual growth rate (CAGR), from $40.52M to $363.73M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Enliven Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude